Details for New Drug Application (NDA): 021269
✉ Email this page to a colleague
The generic ingredient in CARDURA XL is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
Summary for 021269
Tradename: | CARDURA XL |
Applicant: | Viatris |
Ingredient: | doxazosin mesylate |
Patents: | 0 |
Pharmacology for NDA: 021269
Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for 021269
Suppliers and Packaging for NDA: 021269
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269 | NDA | Roerig | 0049-2040 | 0049-2040-10 | 30 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE (0049-2040-10) |
CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269 | NDA | Roerig | 0049-2080 | 0049-2080-10 | 30 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE (0049-2080-10) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 4MG BASE | ||||
Approval Date: | Feb 22, 2005 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 8MG BASE | ||||
Approval Date: | Feb 22, 2005 | TE: | RLD: | Yes |
Expired US Patents for NDA 021269
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viatris | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription